Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Quantum Biopharma Ltd Cls B Subordinate Voting S (QNTM.CN)

Quantum Biopharma Ltd Cls B Subordinate Voting S (QNTM.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Quantum Biopharma Ltd Cls B Subordinate Voting S 55 University Avenue Suite 1003 Toronto ON M5J 2H7 CAN

https://www.quantumbiopharma.com P: 844-978-3540

Sector:

N/A

Description:

Quantum BioPharma Ltd is a biopharmaceutical company dedicated to building a portfolio of inventive assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, it is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, which represents loans secured by residential or commercial property.

Key Statistics

Overview:

Market Capitalization, $K 53,896
Shares Outstanding, K 3,817
Annual Sales, $ 0 K
Annual Net Income, $ -14,203 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -5,319 K
60-Month Beta 1.16
% of Institutional Shareholders 6.90%

Growth:

1-Year Return 131.48%
3-Year Return -80.60%
5-Year Return -90.13%
5-Year Revenue Growth 0.00%

Per-Share Information:

Most Recent Earnings -1.25 on 11/06/25
Next Earnings Date N/A
Earnings Per Share ttm -9.55
EPS Growth vs. Prev Year -32.05%
Dividend Payout Ratio 0.00%
Most Recent Split 1-65 on 08/15/24

QNTM.CN Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -228.60%
Return-on-Assets % -171.84%
Profit Margin % 0.00%
Debt/Equity N/A
Price/Sales N/A
Price/Book 4.46
Book Value/Share 3.16
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar